Quantcast

Latest Daiichi Sankyo Stories

2011-05-23 07:00:00

PARSIPPANY, N.J., May 23, 2011 /PRNewswire/ -- Data evaluating the long-term efficacy and safety of olmesartan medoxomil, amlodipine besylate, plus hydrochlorothiazide (OM/AML + HCTZ) in patients with hypertension aged <65 years and greater than or equal to 65 years, showed that the triple therapy at Week 52 was both well-tolerated and effective in maintaining the blood pressure reductions seen in the pivotal study regardless of age.(1) The pre-specified subgroup analysis results,...

2011-05-20 07:30:00

EAST HANOVER, N.J. and PARSIPPANY, N.J., May 20, 2011 /PRNewswire/ -- During a 'Day of Science,' more than 30 middle school students from Newark Science Park High School experienced what it was like to be scientists for a day during a behind-the-scenes mentoring program hosted by Students 2 Science, Inc. (S2S). The "A Day in the Life of a Scientist" program is one of many integrated full-year science education programs offered by S2S that seeks to address the fact that American high school...

2011-05-17 07:03:00

SHIRLEY, N.Y. and PARSIPPANY, N.J., May 17, 2011 /PRNewswire/ -- Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available. SPRIX® was approved by the U.S. Food and Drug Administration (FDA) in May 2010 for the short-term (up to 5 days) management of...

2011-05-11 05:00:00

PARSIPPANY, N.J. and TOKYO, May 11, 2011 /PRNewswire/ -- Daiichi Sankyo announced that applications have been submitted for market approval for vemurafenib (PLX4032/RG7204) for the treatment of metastatic melanoma to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, a pre-marketing application for approval for a companion diagnostic test has been submitted in the U.S.; the test also will be registered in Europe. Vemurafenib is an oral,...

2011-04-22 07:30:00

TOKYO, April 22, 2011 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that the company has received its first marketing approval for LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan. Edoxaban, which is being developed solely by Daiichi Sankyo, is a once-daily, oral anticoagulant that specifically, reversibly and directly inhibits the enzyme,...

2011-04-20 08:05:00

PARSIPPANY, N.J., April 20, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colesevelam HCI 625 mg tablets. Watson's Colesevelam HCI tablets are a generic version of Daiichi Sankyo, Inc.'s Welchol®. Daiichi Sankyo and Genzyme Corporation filed suit against Watson on...

2011-04-20 07:00:00

PARSIPPANY, N.J. and BETHESDA, Md., April 20, 2011 /PRNewswire/ -- The Sjogren's Syndrome Foundation (SSF), in partnership with Daiichi Sankyo Inc., today announced the launch of the Defy the Dry(TM) campaign, an educational initiative to ignite patient-physician dialogue about dryness symptoms. For those with Sjogren's syndrome today, it takes approximately seven years from the onset symptoms to an accurate diagnosis. Knowing this is too long to wait for a diagnosis, motivated patients...

2011-04-12 04:00:00

FREISING, Germany, April 12, 2011 /PRNewswire/ -- Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply its proprietary Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets. Upon discovery and achievement by Pieris of early preclinical development milestones for lead Anticalin drug...

2011-04-04 07:00:00

PARSIPPANY, N.J., April 4, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that John P. Gargiulo has been appointed President and CEO of the company. Effective today, Mr. Gargiulo succeeds Joseph P. Pieroni who is retiring after leading Daiichi Sankyo Group's U.S. commercial operations for the past 14 years. "John's experiences within the pharmaceutical industry for the past 25 years have prepared him well for his new role and responsibility," said Joseph Pieroni, former...

2011-03-29 12:34:00

PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 /PRNewswire/ -- Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention (PCI) after experiencing heart-related chest pain at rest (unstable angina) or non-ST segment elevation myocardial infarction (NSTEMI). NSTEMI is a type of heart attack that that does not need to be...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.